VasBlock 80mg Medochemie Treatment of hypertension, heart failure (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Valsartan

Ingredient

Composition informationContent
Valsartan80mg

Uses

Indications

vasblock 80mg indicated in the following cases:

  • Hypertension: Treatment of hypertension. As a supportive therapy for angiotensin transferring enzymes inhibitors when they cannot use beta blockers. It selectively acts on the AT1 receptor, which is responsible for the known effects of Angiotensin II.

    The concentration of angiotensin II in plasma increases after the AT1 receptor is inhibited because Valsartan can stimulate the AT2 receptor not inhibited, which balances the effect of the AT1 receptor. Valsartan does not show any partial activity at AT1 receptor and has a higher AT1 receptor (about 20,000 times higher) than the AT2 receptor.

    Valsartan does not inhibit angiotensin transfer enzymes (also known as Kininase II), is the enzyme that converts angiotensin I into angiotensin II and bradykinin. Because there is no effect on angiotensin transfer enzymes and not strengthening the effects of Bradykinin or P substance, Angiotensin II antagonists are not necessarily related to cough.

    In clinical trials that Valsartan is compared to an angiotensin transfer inhibitor, the rate of dry cough is significantly lower (p

    In a clinical trial in patients with a history of dry cough while being treated with enzyme inhibitors, 19.5% of patients in the test have used Valsartan and 19% of patients who are taking thiazid diuretics with coughs compared to 68.5% of patients treated with enzyme inhibitors (P

    Valsartan is not attached or not blocking other hormones or ion channels known to be important in the cardiovascular regulation.

    pharmacokinetics

    absorption:

  • After taking Valsartan tablets, the plasma peak concentration of Valsartan is achieved in 2-4 hours. Similar to each other for eating and fasting group.
  • The volume of distribution in the stable state of Valsartan after intravenous injection is about 17 liters, showing that Valsartan is not distributed into tissues widely. Valsartan is strongly connected to serum protein (94-97%), mainly in serum albumin.

    • Metabolic:

  • Valsartan is under low biological change, only about 20% of the dose is found in the form of metabolites.
  • Valsartan has a dynamic dynamic decay according to the abundant function (t ½α In patients with heart failure:
  • Time to achieve the average peak concentration and the sale time of Valsartan in heart failure patients similar to being observed in healthy volunteers.
  • The apparent clearance of Valsartan after drinking is about 4.5 liters/hour.

    Elderly: Pharmacokinetic parameters for Valsartan in the elderly are a bit higher than young people, but this has not seen any clinical meaning.

    Patients with renal function impairment:

  • As may be encountered for a substance where the kidney clearance accounts for only 30% of the total plasma clearance, not recognizing the relevance between the kidney function and the body contact level for Valsartan. 10ml/minute and the patient is fecal. Valsartan is strongly connected to plasma proteins and is not sure to be removed by fertilizer.

    • Patients with liver failure:

  • About 70% of the absorption dose is excreted in bile mainly in the form of constant drugs.

    • Before taking VasBlock 80mg Medochemie Treatment of hypertension, heart failure (3 blisters x 10 tablets)

    How to use

    vasblock can drink with or not with meals and should be taken with water.

    Dosage

    adults

    Dosage for hypertension treatment:

  • The recommended starting dose is 80 mg every day. Simultaneous use with diuretics can also reduce blood pressure in these patients.
  • In clinical stabilizers, treatment may start early 12 hours after myocardial infarction. Recommendation of 80 mg, 2 times/2 weeks after the beginning of treatment and the maximum destination dose achieved after 3 months, based on the patient's tolerance to Valsartan. If you occur symptomatic blood pressure or kidney dysfunction, the dose reduction. It is not recommended to simultaneously use Valsartan with Angiotensin (ACE). .

    When assessing patients with myocardial infarction must always include kidney function assessment.

    Dosage treatment for patients with heart failure:

  • The recommended starting dose is 40 mg, 2 times/day.
  • Valsartan can be used in combination with other heart failure drugs, but it is not recommended to use simultaneously with angiotensin (ACE) and beta blockers.

    Patients with renal impairment: No need to adjust the dose in patients with Creatinin clearance> 10ml/min.

    Patients with liver failure:

  • Valsartan is contraindicated in patients with severe liver failure, bile cirrhosis and cholestasis.

    Children with high blood pressure:

    Children from 6 to 18 years old:

    The starting dose of 40 mg once a day in children weighs less than 35kg and 80 mg once a day in children weighing over 35kg. Dosage can be adjusted depending on the response of the patient.

    Do not overdose to the maximum recommended by the following table:

    Weight Maximum recommendations recommended 320 mg

    Children from 6 to 18 years of renal failure:

  • The safety and effectiveness of Valsartan in children with creatinine clearance Children from 6 to 18 years of age: No clinical experience using Valsartan for children with light to moderate, dose Valsartan should not exceed 80 mg.

    Children with heart failure and after myocardial infarction: The safety and effectiveness of Valsartan in children with heart failure and after the unchanged myocardial infarction.What do

    do when overdose?

    If hypotension occurs, patients should be placed in a lying position and should consider adjusting blood volume.

    Valsartan is not sure to be removed by hemorrhage.

    What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

    • Side Effects

    In verified clinical studies in patients with hypertension, the overall frequency of side effects (ADRS) is compared with the placebo and in accordance with the pharmacological properties of Valsartan. The frequency of side effects is not related to dosage or treatment time and also shows that it is not related to gender, age or race.

    Side reactions are reported from clinical studies, after -sales experience and subclinical results listed in the table below by organ system groups.

    Side reactions are ranked by frequency, first is most common, using the following convention: very common (≥1/10); Or meet (≥1/100,

    For side effects reported from after -sales experience and subclinical results cannot be arranged in any frequency of side effects and therefore they are mentioned with the frequency of "unknown".

    Cardiovascular: Brushing chest drum, chest pain.

    Notify the doctor with unwanted effects when using the drug.

    Instructions on how to handle ADR

    During the controlled clinical research in people with hypertension, the ADR is equivalent to the Valsartan treatment group and the Placebo group. ADR frequency does not depend on the dose, treatment time, age, gender or ethnicity.

    Warnings

    Before using the drug you need to read the instructions carefully and refer to the information below.

    contraindicated

    vasblock 80mg contraindicated in the following cases:

  • It is known that hypersensitivity to Valsartan or any excipients of the drug.

    Caution when using

    Patients with renal function: No dose adjustment for patients with renal failure. However, there is no data on severe cases (creatinine clearance

    Patients with liver failure:

  • No dose adjustment for patients with liver failure. Severe fluid as being treated with high -dose dosage, rare hypotension after the beginning of Valsartan treatment.

    Patients with renal artery stenosis:

  • Using Valsartan in a short time for 12 patients with hypertension due to secondary kidney blood vessels after the narrow artery stenosis of the one side does not cause significant changes in kinetic hemodynamics in the kidney, serum creatinine or blood urea nitrogen (bun). Serum creatinine in patients with kidney stenosis on both sides or one side, recommend monitoring both of the above parameters as safety measures.

    • Patients with heart failure/myocardial infarction:

    Using Valsartan in patients with heart failure or after myocardial infarction often leads to a part of blood pressure, but stopping the use of valsartan due to lowering blood pressure is often not needed as long as the dose is in accordance with the instructions.

    The impact of drugs on drivers and operating machinery

    The effect of drugs on driving and operating machinery: There are no reports on the effects of the drug on the ability to drive and operate machinery, but the drug users should be cautious when driving and operating machinery because the drug can cause dizziness and fatigue.

    used for pregnant and lactating women

    Pregnancy: Angiotensin II receptor antagonistic group is not recommended for use in the first 3 months of pregnancy and contraindicated in the second and third trimester of pregnancy.

    studies in male and female rats do not show any effects of Valsartan on fertility when using the dose up to 200 mg/kg/day. This dose is 6 times the maximum dose recommended for people calculated on mg/m2 (corresponding to oral dose of 320 mg/day for patients 60kg).

    Breastfeeding period: It is unclear whether Valsartan is excreted in breast milk or not. Do not recommend valsartan in breastfeeding mothers.

    Drug interaction

    should not be coordinated:

    Lithi: Increased lithium lithium concentration and toxicity have been reported when used simultaneously lithium with enzyme inhibitors. Do not recommend using valsartan with lithium, if necessary to coordinate, should monitor serum lithium concentration.

    Potassium diuretics, potassium supplements, salt -containing substances containing potassium and other substances can lead to hyperkalemia: If it is necessary to coordinate valsartan with drugs that affect potassium concentration, plasma potassium levels should be monitored.

    Precautions when coordinating:

    Non-steroid anti-inflammatory drugs, including COX-2 inhibitors, acetylsalicylic acid (> 3G/day), and non-selective nonsteroidal anti-inflammatory drugs:

  • Use Angiotensin II receptor antagonist at the same time with nonsteroidal anti -inflammatory drugs that can reduce the effectiveness of hypotension. If you have to coordinate, you should monitor kidney function at the beginning of treatment and the patient must drink enough water during treatment.

    • There is no clinical interaction that is recorded between Valsartan and the following drugs: Cimetidin, Warfarin, Furosemid, Digoxin, Atenolol, Indometacin, Hydrochlorothiazide, Amlodipin, Glibenclamid.

    Storage

    Leave a cool place, avoid light, temperature below 30⁰C.

    Other drugs

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    count views

    Popular Keywords